Purple Biotech Highlights Positive Phase 2 Data for CM24 and Advances Lead Program IM1240 to Phase 1

summarizeZusammenfassung

Purple Biotech's updated corporate presentation outlines significant progress across its oncology pipeline and confirms a solid financial runway. The company reported positive Phase 2 efficacy data for CM24 in pancreatic cancer, showing a notable reduction in the risk of death and progression, particularly in biomarker-enriched patient populations. This data positions CM24 for potential partnership. Additionally, its lead CAPTN-3 platform asset, IM1240, is on track for IND submission in Q3 2026 and Phase 1 initiation in H2 2026, representing a key de-risking event for the novel tri-specific antibody platform. The company also confirmed a cash runway into H1 2027, providing funding for these critical milestones and reducing near-term financing concerns for this micro-cap biotech.

check_boxSchlusselereignisse

• Positive CM24 Phase 2 Data

  CM24 demonstrated a 19% reduction in the risk of death and a 25% reduction in the risk of progression or death in metastatic pancreatic cancer patients, with even stronger results in biomarker-enriched populations.

• Lead Program IM1240 Progress

  The CAPTN-3 platform's lead asset, IM1240, completed GLP toxicology studies and is slated for IND submission in Q3 2026 and Phase 1 initiation in H2 2026.

• Extended Cash Runway

  The company's cash position provides a runway into H1 2027, covering key development milestones for its pipeline.

• Multiple 2026 Catalysts

  Several value-creating milestones are anticipated in 2026, including interim data for NT219 and potential CM24 partnerships.

auto_awesomeAnalyse

Purple Biotech's updated corporate presentation outlines significant progress across its oncology pipeline and confirms a solid financial runway. The company reported positive Phase 2 efficacy data for CM24 in pancreatic cancer, showing a notable reduction in the risk of death and progression, particularly in biomarker-enriched patient populations. This data positions CM24 for potential partnership. Additionally, its lead CAPTN-3 platform asset, IM1240, is on track for IND submission in Q3 2026 and Phase 1 initiation in H2 2026, representing a key de-risking event for the novel tri-specific antibody platform. The company also confirmed a cash runway into H1 2027, providing funding for these critical milestones and reducing near-term financing concerns for this micro-cap biotech.